Department of Neurology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania.
Department of Biostatistics and Epidemiology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania.
Ann Clin Transl Neurol. 2016 Mar 29;3(5):346-55. doi: 10.1002/acn3.299. eCollection 2016 May.
Cognitive decline occurs in multiple neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson's disease (PD). Shared underlying mechanisms may exist and manifest as shared biomarker signatures. Previously, we nominated plasma epidermal growth factor (EGF) as a biomarker predicting cognitive decline in patients with established PD. Here, we investigate EGF as a predictive biomarker in prodromal PD, as well as AD.
A cohort of PD patients (n = 236) was recruited to replicate our finding that low baseline EGF levels predict future cognitive decline. Additionally, plasma EGF and cognitive outcome measures were obtained from individuals with normal cognition (NC, n = 58), amnestic mild cognitive impairment (AD-MCI, n = 396), and Alzheimer's disease (AD, n = 112) in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort to investigate whether low EGF levels correlate with cognitive status and outcome in AD-MCI and AD. Third, plasma EGF and cognitive measures were evaluated in the high-risk asymptomatic Parkinson's Associated Risk Study (PARS) cohort (n = 165) to investigate the association of EGF and cognitive performance in a PD prodromal context.
In both PD and AD-MCI, low baseline plasma EGF predicted poorer long-term cognitive outcomes. In asymptomatic individuals at highest risk for developing PD from the PARS cohort, low baseline plasma EGF associated with poorer performance in the visuospatial domain but not in other cognitive domains.
Low plasma EGF at baseline predicts cognitive decline in both AD and PD. Evidence for this signal may exist in prodromal stages of both diseases.
认知能力下降发生于多种神经退行性疾病，包括阿尔茨海默病（AD）和帕金森病（PD）。可能存在共同的潜在机制，并表现为共同的生物标志物特征。此前，我们提出血浆表皮生长因子（EGF）是预测已确诊 PD 患者认知能力下降的生物标志物。在此，我们研究 EGF 作为前驱期 PD 和 AD 的预测性生物标志物。
我们招募了一组 PD 患者（n = 236）来复制我们的发现，即低基线 EGF 水平预测未来认知能力下降。此外，我们从具有正常认知（NC，n = 58）、遗忘型轻度认知障碍（AD-MCI，n = 396）和阿尔茨海默病（AD，n = 112）的个体中获得了 ADNI 队列中的血浆 EGF 和认知结果测量值，以研究低 EGF 水平是否与 AD-MCI 和 AD 中的认知状态和结果相关。第三，我们在高风险无症状帕金森病相关风险研究（PARS）队列（n = 165）中评估了血浆 EGF 和认知测量值，以研究在 PD 前驱期背景下 EGF 和认知表现的关联。
在 PD 和 AD-MCI 中，低基线血浆 EGF 预测了较差的长期认知结局。在来自 PARS 队列的 PD 发病风险最高的无症状个体中，低基线血浆 EGF 与视空间域较差的表现相关，但与其他认知域无关。
低基线血浆 EGF 可预测 AD 和 PD 中的认知能力下降。在这两种疾病的前驱期可能存在这种信号的证据。
Zotero 插件